William Blair Issues Negative Outlook for Exagen Earnings

Exagen Inc. (NASDAQ:XGN) – William Blair lowered their Q2 2025 earnings estimates for shares of Exagen in a research note issued on Monday, May 5th. William Blair analyst A. Brackmann now anticipates that the company will post earnings of ($0.18) per share for the quarter, down from their prior forecast of ($0.16). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share. William Blair also issued estimates for Exagen’s Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.61) EPS and FY2026 earnings at ($0.25) EPS.

A number of other equities analysts have also recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $8.00 price target on shares of Exagen in a research note on Monday, January 13th. BTIG Research reissued a “buy” rating on shares of Exagen in a research note on Wednesday.

Exagen Stock Down 7.3 %

XGN stock opened at $5.71 on Thursday. The company’s 50 day moving average is $4.54 and its 200 day moving average is $4.11. The stock has a market cap of $102.79 million, a price-to-earnings ratio of -6.07 and a beta of 1.50. The company has a current ratio of 4.05, a quick ratio of 4.05 and a debt-to-equity ratio of 1.54. Exagen has a 1-year low of $1.38 and a 1-year high of $7.20.

Exagen (NASDAQ:XGN) last announced its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.20). Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. The business had revenue of $15.50 million for the quarter, compared to analyst estimates of $14.55 million. During the same period in the prior year, the company earned ($0.19) EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of XGN. Huntleigh Advisors Inc. boosted its stake in shares of Exagen by 16.8% in the 1st quarter. Huntleigh Advisors Inc. now owns 83,108 shares of the company’s stock valued at $298,000 after purchasing an additional 11,939 shares in the last quarter. Palumbo Wealth Management LLC lifted its stake in Exagen by 14.4% in the first quarter. Palumbo Wealth Management LLC now owns 99,205 shares of the company’s stock worth $356,000 after purchasing an additional 12,501 shares during the last quarter. Toronto Dominion Bank purchased a new stake in Exagen during the fourth quarter valued at about $3,655,000. Driehaus Capital Management LLC bought a new position in shares of Exagen during the fourth quarter valued at about $1,716,000. Finally, Northern Trust Corp grew its stake in shares of Exagen by 16.7% during the fourth quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock valued at $75,000 after buying an additional 2,630 shares during the last quarter. 75.25% of the stock is currently owned by institutional investors.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).